

Communicable Diseases and Immunization Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

PDate: October 31, 2018 Administrative Circular: 2018:15

**ATTN:** Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 1: Meningococcal Disease and Chapter 2: Immunization, Part 2 – Immunization of Special Populations and Part 4 – Biological Products

## **Chapter 1: Meningococcal Disease**

- 'Communicable Diseases and Immunization Service, BCCDC' has replaced the previous service line name of 'Immunization Programs and Vaccine Preventable Diseases Service, BCCDC'.
- The after-hours phone number for the immediate reporting of cases and contacts has been revised with the new after-hours number.

Please remove page numbers: 4, 5 & 13 dated June and September 2017 Please add new page numbers: 4, 5 & 13 dated October 2018

#### Chapter 2: Immunization

#### Part 2 - Immunization of Special Populations

#### Specific Immunocompromising Conditions

#### **Human Immunodeficiency Virus (HIV) Infection**

- The table "Recommended vaccines for those with HIV infection" has been revised to
  indicate that infants who are exposed to or infected with HIV should be immunized with
  rotavirus vaccine according to the routine schedule. Subsequent content related to
  rotavirus vaccine in this subsection has been updated accordingly.
- Oral cholera vaccine has been removed from the list of live vaccines as an inactivated preparation is used in Canada.

Please remove page numbers: 1 & 2 dated January 2017 Please add new page numbers: 1 & 2 dated October 2018







# **Other High Risk Conditions**

# Women Who are Pregnant or Planning a Pregnancy

Footnote B related to Tdap vaccine has been updated as per the most recent NACI recommendation.

Please remove page numbers: 1 & 2 dated May 2016 Please add new page numbers: 1 & 2 dated October 2018

# Part 4 – Biological Products

## Pneumococcal Vaccines

## Pneumococcal Polysaccharide Vaccine (Pneumovax® 23)

 Solid organ or islet cell transplant (candidate or recipient) has been added to the list of those for whom a once-only revaccination should be offered 5 years after the initial immunization.

> Please remove page numbers: 1 & 2 dated October 2017 Please add new page numbers: 1 & 2 dated October 2018

### **Rabies Vaccines**

#### Rabies Vaccine for POST-EXPOSURE Prophylaxis (IMOVAX® Rabies and RabAvert®)

• SEROLOGICAL TESTING AND RE-VACCINATION has been revised to remove the recommendation for post-series serological testing for those on chloroquine.

Please remove page numbers: 1-3 dated May 2017 Please add new page numbers: 1-3 dated October 2018


#### **Rotavirus Vaccines**

#### **Rotarix®**

 CONTRAINDICATIONS: Footnote E has been added to indicate that infants exposed to or infected with HIV should be immunized with rotavirus vaccine according to the routine schedule.

> Please remove page numbers: 1-3 dated April 2018 Please add new page numbers: 1-3 dated October 2018





# BC Centre for Disease Control An agency of the Provincial Health Services Authority

#### **RotaTeq®**

 CONTRAINDICATIONS: Footnote E has been added to indicate that infants exposed to or infected with HIV should be immunized with rotavirus vaccine according to the routine schedule.

> Please remove page numbers: 1-3 dated April 2018 Please add new page numbers: 1-3 dated October 2018

#### **Zoster Vaccines**

### **Shingrix®**

• The new product page for recombinant zoster vaccine (SHINGRIX®) has been added.

Please add new page numbers: 1 & 2 dated October 2018

#### Zostavax® II

- The section "Recommended by the National Advisory Committee on Immunization but not Provided Free in BC" has been revised to indicate that Zostavax® II may be considered when recombinant zoster vaccine (Shingrix®) is contraindicated or unavailable.
- CONTRAINDICATIONS has been revised to include that pregnancy should be avoided for 3 months following live zoster immunization.
- PRECAUTIONS has been revised to include that live zoster vaccine should be used with precaution in those who are breastfeeding.
- CONTRAINDICATIONS, Footnote B, has been updated to indicate that live zoster vaccine
  can be considered for those receiving topical, inhaled or low-dose immunosuppressive
  therapy.

Please remove page numbers: 1 & 2 dated March 2017 Please add new page numbers: 1 & 2 dated October 2018

Please also remove the Table of Contents for Part 4 – Biological Products dated August 27, 2018 and replace with the enclosed updated Table of Contents dated October 2018.





# BC Centre for Disease Control An agency of the Provincial Health Services Authority

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: <a href="mailto:christine.halpert@bccdc.ca">christine.halpert@bccdc.ca</a>) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: <a href="mailto:stephanie.meier@bccdc.ca">stephanie.meier@bccdc.ca</a>).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM

**Medical Director** 

Communicable Diseases & Immunization Service

BC Centre for Disease Control

dite bans

pc:

Provincial Health Officer

Dr. Bonnie Henry

Dr. Mark Tyndall

**Executive Medical Director** 

BC Centre for Disease Control, and

Deputy Provincial Health Officer

BC Ministry of Health, Population & Public Health Division:

Craig Thompson

Director, Immunization

Wendy Trotter

Executive Director,

**Public Health Services** 



